Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Chief Medical Officer | February 02, 2018 | February 06, 2018 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | President, R&D | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mersana Therapeutics, Inc.
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.23 · Expires 2028-02-01 | Direct | 56,884 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 56,884 · Balance 56,884 F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018.
Relay Therapeutics, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 399,130 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 8,530 · Balance 399,130 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 10,025 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 10,025 shares underlying restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2022 Filed Nov 1, 2022 21:58 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $22.75 | $182,000.00 |
DisclosureSEC source: 0001209191-22-055116 · doc4.xml · nonDerivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,866 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.48 to $23.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 74,647 shares underlying RSUs. Read SEC document |
| November 01, 2022 Filed Nov 1, 2022 21:58 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-055116 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 74,647 shares underlying RSUs. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 21:58 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,817 | $21.54 | $39,138.18 |
DisclosureSEC source: 0001209191-22-055116 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,866 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 4,060 shares of restricted stock units ("RSUs") on October 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 74,647 shares underlying RSUs. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-052221 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $22.43 | $179,440.00 |
DisclosureSEC source: 0001209191-22-052221 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,683 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.09 to $22.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 78,707 shares underlying restricted stock units. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-052221 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 78,707 shares underlying restricted stock units. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 21:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 976 | $22.73 | $22,184.48 |
DisclosureSEC source: 0001209191-22-051542 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,683 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on September 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 78,707 shares underlying RSUs. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-049242 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,456 Underlying: Common Stock · 25,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 25,000 | $30.00 | $750,000.00 |
DisclosureSEC source: 0001209191-22-049242 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,659 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 25,000 | $4.12 | $103,000.00 |
DisclosureSEC source: 0001209191-22-049242 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 21:47 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-048561 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,456 Underlying: Common Stock · 4,900 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 21:47 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 4,900 | $25.46 | $124,754.00 |
DisclosureSEC source: 0001209191-22-048561 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,659 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| September 02, 2022 Filed Sep 2, 2022 21:47 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 4,900 | $4.12 | $20,188.00 |
DisclosureSEC source: 0001209191-22-048561 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 00:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-048391 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,356 Underlying: Common Stock · 8,100 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 00:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,100 | $23.07 | $186,867.00 |
DisclosureSEC source: 0001209191-22-048391 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,659 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.63 to $25.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 00:26 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,100 | $4.12 | $33,372.00 |
DisclosureSEC source: 0001209191-22-048391 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 21:23 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-047560 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,456 Underlying: Common Stock · 15,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 21:23 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 15,000 | $25.00 | $375,000.00 |
DisclosureSEC source: 0001209191-22-047560 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,659 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 21:23 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 15,000 | $4.12 | $61,800.00 |
DisclosureSEC source: 0001209191-22-047560 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-044859 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001209191-22-044859 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,659 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-044859 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 80,894 shares underlying restricted stock units. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:45 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,835 | $21.27 | $39,030.45 |
DisclosureSEC source: 0001209191-22-043536 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,659 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 4,059 shares of restricted stock units ("RSUs") on July 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 80,894 shares underlying RSUs. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-041628 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001209191-22-041628 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,494 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 84,953 shares underlying restricted stock units. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-041628 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 84,953 shares underlying restricted stock units. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 21:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 999 | $20.31 | $20,289.69 |
DisclosureSEC source: 0001209191-22-039654 · doc4.xml · nonDerivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,494 F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of RSUs on June 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4 · balance_after: Includes 84,953 shares underlying RSUs. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 21:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-039654 · doc4.xml · derivative · entry 4 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 21:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $20.00 | $160,000.00 |
DisclosureSEC source: 0001209191-22-039654 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,493 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 87,141 shares underlying restricted stock units ("RSUs"). Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 21:53 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-039654 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 87,141 shares underlying restricted stock units ("RSUs"). Read SEC document |
| June 14, 2022 Filed Jun 22, 2022 19:03 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-22-038765 · doc4.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| May 02, 2022 Filed May 3, 2022 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-026535 · doc4.xml · derivative · entry 4 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,456 Underlying: Common Stock · 13,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| May 02, 2022 Filed May 3, 2022 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 13,000 | $24.62 | $320,060.00 |
DisclosureSEC source: 0001209191-22-026535 · doc4.xml · nonDerivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,493 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $23.09 to $25.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 87,141 shares underlying RSUs. Read SEC document |
| May 02, 2022 Filed May 3, 2022 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 13,000 | $4.12 | $53,560.00 |
DisclosureSEC source: 0001209191-22-026535 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 87,141 shares underlying RSUs. Read SEC document |
| April 28, 2022 Filed May 3, 2022 00:24 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 1,811 | $25.57 | $46,307.27 |
DisclosureSEC source: 0001209191-22-026535 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,493 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 4,059 shares of restricted stock units ("RSUs") on April 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 87,141 shares underlying RSUs. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:32 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-023203 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,456 Underlying: Common Stock · 18,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:32 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,000 | $30.32 | $545,760.00 |
DisclosureSEC source: 0001209191-22-023203 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,304 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $29.91 to $30.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 91,200 shares underlying restricted stock units. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:32 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 18,000 | $4.12 | $74,160.00 |
DisclosureSEC source: 0001209191-22-023203 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 91,200 shares underlying restricted stock units. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:41 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 622 | $29.87 | $18,579.14 |
DisclosureSEC source: 0001209191-22-021820 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,304 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on March 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 91,200 shares underlying RSUs. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021388 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,456 Underlying: Common Stock · 10,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-22-021388 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,926 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:11 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 10,000 | $4.12 | $41,200.00 |
DisclosureSEC source: 0001209191-22-021388 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 00:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-018291 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,456 Underlying: Common Stock · 10,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 00:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001209191-22-018291 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,926 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 00:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 10,000 | $4.12 | $41,200.00 |
DisclosureSEC source: 0001209191-22-018291 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-015724 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $23.88 | $191,040.00 |
DisclosureSEC source: 0001209191-22-015724 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,926 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.23 to $24.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-015724 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 02:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-011991 · doc4.xml · derivative · entry 5 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,456 Underlying: Common Stock · 8,000 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 02:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 2,752 | $20.97 | $57,709.44 |
DisclosureSEC source: 0001209191-22-011991 · doc4.xml · nonDerivative · entry 4 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,926 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $20.76 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.